Compare Crispr Therapeutics AG (CRSP) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hershey Co — how do they compare? Crispr Therapeutics AG trades at $54.01 (market cap $5.23B), while Hershey Co trades at $184.8 (market cap $36.56B). The key difference: Hershey Co is far larger — about 7× Crispr Therapeutics AG's market cap, and Hershey Co pays a 3.19% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HSY | |
|---|---|---|
Market Cap | $5.23B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $236.28 |
52-Week Low | $44.34 | $162.31 |
Enterprise Value | $3.65B | $41.70B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Hershey (HSY) trades at $184.19, up 0.79% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth remains steady at $11.69 billion for 2025. Technical indicators show bullish momentum with the current price near resistance at $184, supported by positive moving average signals. The company maintains robust profitability with 38.38% gross margins and 32.81% ROE, though net income declined to $883 million in 2025 from previous highs.
HSY presents a favorable risk-reward profile with analyst consensus target of $196.78 offering 7% upside potential. Recent margin recovery from favorable cocoa contracts and dividend growth support bullish sentiment, though volume declines and competitive pressures in salty snacks remain concerns. With 68.57% of analysts maintaining Hold ratings, the stock offers steady growth potential but requires monitoring of consumer demand trends and input cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
